What is Zepbound?

Zepbound is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off . Zepbound should be used with a reduced-calorie diet and increased physical activity Zepbound 10mg.

• Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines.
• It is not known if Zepbound is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products.
• It is not known if Zepbound can be used in people who have had pancreatitis.
• It is not known if Zepbound is safe and effective for use in children under 18 years of age.

Tirzepatide has a unique mechanism of action that sets it apart from other weight-loss medications. It activates two hormone receptors in the body called GIP and GLP-1 receptors. GLP-1 is a hormone that helps regulate appetite and food intake. Based on preliminary lab studies, GIP is another hormone that may further reduce food cravings and calorie consumption when combined with GLP-1. It is designed to supplement diet and exercise and helps with chronic weight management.

Zepbound 10mg for weightloss

(Tizepatide) is still awaiting registration with the Therapeutic Goods Administration (TGA), USA’s medicine safety and governing body. Zepbound contains the same active ingredients as Mounjaro (Tizepatide) but for a different therapeutic use and has been cleared by the USA’s Food and Drug Administration (FDA) as well as the UK’s medicines regulator in late 2023.

Before release in USA Zepbound manufacturer Eli Lilly will need to gain approval from the TGA and secure enough stock to adequately and consistently meet demand in the USA market. This is particularly important as Zepbound, like other GLP-1 receptor agonist treatments, is likely to experience high demand and have complex storage, transport and manufacturing challenges to keep up with it